Results 131 to 140 of about 7,770 (204)

Biologics and biosimilars medication errors in Saudi Arabia: a nationwide retrospective observational real-world study. [PDF]

Front Med (Lausanne)
Alshammri NT, Alluwaymi WS, Assiri GA, Alshammari TM.   +3 more
europepmc   +1 more source

Horizon scan of the clinical development landscape of biosimilar products in the UK and EU. [PDF]

Int J Technol Assess Health Care
Hussain A, Fairbairn R, Khan SK.
europepmc   +1 more source

Comparing the pharmacokinetics of adalimumab originator and biosimilar product in patients with Inflammatory bowel disease or autoimmune disease. [PDF]

Saudi Pharm J
Drweesh H, Alotaibi A, Alqassim HA, Eid MM, Emsaad SA, Saad MO, Higazy AS, Alturaiki A, Almutairi F, Alhussain A, Assiri A, Alkofide H, Alruthia Y, Albassam A, Alsultan A.   +14 more
europepmc   +1 more source

Migraine, monoclonal antibodies, and monitoring: a review of pharmacovigilance in the era of biologics. [PDF]

Front Pharmacol
Guarnieri L, Bosco F, Corasaniti MT, Citraro R, De Sarro G.   +4 more
europepmc   +1 more source

Non-signaling protein therapeutics: a mechanism-based regulatory framework to modernize biosimilar development and global harmonization. [PDF]

Front Med (Lausanne)
Niazi SK.
europepmc   +1 more source

Comparable remission and health care use in real-world inflammatory bowel disease patients initiating originator biologics <i>vs</i> biosimilars. [PDF]

World J Gastroenterol
Moura CS, Etingin A, Lukusa L, Singh H, Narula N, Targownik LE, Leung Y, Zezos P, Polewiczowska-Nowak B, Afif W, Bernatsky S.   +10 more
europepmc   +1 more source

Tocilizumab: From Bench to Bedside - A Comprehensive Review. [PDF]

Kans J Med
Khoury A, El Halabi L, Al Bayeh A, Katrib M, Nasr J, Reddy P.   +5 more
europepmc   +1 more source

Measuring the Impact of the Substitution of Innovator Biologics With Biosimilars on Uptake and Costs Among Ontario Public Drug Benefit Recipients. [PDF]

Clin Pharmacol Ther
Iacono A, Ho MKH, Yang J, Campbell T, Wynne W, Shearer D, Andersen L, Majer E, Ledlie S, Tadrous M, Gomes T.   +10 more
europepmc   +1 more source

Demonstrating interchangeability and biosimilarity for US biosimilars [PDF]

Generics and Biosimilars Initiative Journal, 2016
openaire   +1 more source

Effectiveness and safety of adalimumab biosimilar in bio-naive patients with inflammatory bowel disease: a real-life multicenter observational study comparing ABP501, SB5, MSB11022, GP2017, and FKB327. [PDF]

Crohns Colitis 360
Regueiro C, Vázquez Rey MT, Bastón-Rey I, Galego MA, Campos AC, Baz López AM, Arriero GM, Ruiz Barcia MJ, Villaamil PV, EIGA.   +9 more
europepmc   +1 more source